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Fibrosis, a disease that results in loss of organ function, contributes to a significant number of deaths worldwide
and sustained fibrotic activation has been suggested to increase the risk of developing cancer in a variety of tissues.
Fibrogenesis and tumor progression are regulated in part through the activation and activity of myofibroblasts.
Increasing evidence links myofibroblasts found within fibrotic lesions and the tumor microenvironment to a process
termed epithelial-mesenchymal transition (EMT), a phenotypic change in which epithelial cells acquire mesenchymal
characteristics. EMT can be stimulated by soluble signals, including transforming growth factor (TGF)-β, and recent
studies have identified a role for mechanical cues in directing EMT. In this review, we describe the role that EMT
plays in fibrogenesis and in the progression of cancer, with particular emphasis placed on biophysical signaling
mechanisms that control the EMT program. We further describe specific TGFβ-induced intracellular signaling
cascades that are affected by cell- and tissue-level mechanics. Finally, we highlight the implications of mechanical
induction of EMT on the development of treatments and targeted intervention strategies for fibrosis and cancer.
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Fibrotic diseases promote loss of function in a variety of
organs including the heart, liver, lung, and kidney resul-
ting in a significant number of deaths worldwide [1,2].
Fibrosis arises from deregulation of wound healing pro-
cesses and is characterized by a stiff and collagen-rich
extracellular matrix (ECM) that is resistant to degrad-
ation. Inappropriate activation and activity of myofibro-
blasts drives the development of fibrosis. An increased
risk of developing cancer in a variety of tissues has been
linked to high stromal collagen content and to the pres-
ence of fibrotic lesions [3-5]. Indeed, fibrosis has been
found in close proximity of tumors within the pancreas
[6], liver [7], and kidney [8] and myofibroblasts have
been identified as residents of the tumor microenviron-
ment [9,10]. The purpose of this article is to review the* Correspondence: ewgomez@engr.psu.edu
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reproduction in any medium, provided the origrole of myofibroblasts in fibrosis and cancer and to discuss
how physical cues contribute to epithelial-mesenchymal
transition and to the development of myofibroblasts.Review
Myofibroblasts in health and disease
Myofibroblasts are specialized cells within the body that
aid in wound healing. Upon activation by biochemical
and mechanical signals, myofibroblasts secrete and or-
ganize ECM, develop specialized matrix adhesions [11],
and exhibit cytoskeletal organization characterized by
contractile actin filaments [12]. Together, these features
allow for re-establishment of mechanical integrity and
stability to the damaged tissue and enable the myofibro-
blasts to exert large contractile forces on their micro-
environment thus assisting in both the closure of the
wound and remodeling of the tissue [13,14]. When wound
healing is complete, myofibroblasts undergo apoptosis
which decreases the cellularity of the granulation tissue
and promotes the formation of scar tissue [15]. Due
to their important role in wound healing, these cellsr. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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cine applications.
Upon aberrant and chronic activation, myofibroblasts
can mediate the development of fibrosis [16-20]. The
sustained activation of myofibroblasts results in the en-
hanced production of ECM components, including col-
lagen types I, III, IV, V, and VI and fibronectin [21-23].
Through integrin engagement with ECM components
and cytoskeletal contractility, myofibroblasts exert large
forces on the ECM thus enabling matrix assembly and
alignment [24]. Together, these factors can lead to stiff-
ening of the tissue and disruption of tissue architecture
and function.
Studies suggest that myofibroblasts are key players in
the progression of a variety of cancer types including
lung [5], liver [3,25], breast [26], and gastric [27] cancer.
Myofibroblasts have been found at the invasive fronts of
tumors where they secrete pro-invasive cytokines, prote-
ases, and inflammatory mediators [28-36]. Fibrotic le-
sions and myofibroblasts have also been found in the
tumor microenvironment prior to cancer cell invasion
into the stroma suggesting that myofibroblasts may me-
diate an invasive phenotype [37]. Indeed, myofibroblasts
are found in higher proportions in the stroma of invasive
breast cancers than in in situ carcinoma and their pres-
ence has been correlated with lymph node metastasis
and increased histological grade in invasive ductal car-
cinoma [38,39]. Contrary to these reports, a recent study
found that myofibroblasts may serve a protective role in
the context of pancreatic cancer as depletion of myofi-
broblasts and fibrosis in a mouse model of pancreatic
ductal adenocarcinoma leads to a more invasive cancer
cell phenotype and reduced survival [40]. Depletion of
myofibroblasts promoted remodeling of the pancreatic
tumor stroma as well as changes in immune cell infiltra-
tion to the tumor. Thus, the effect of myofibroblasts on
cancer progression appears to be complex and multifa-
ceted and may vary depending upon organ or stage of
cancer. Future investigation of the effect of in vivo
myofibroblast depletion in other cancer types will be
informative and will shed further light on the role of
myofibroblasts in tumor progression.
Differentiation of myofibroblasts from fibroblasts
Following the identification of myofibroblasts, studies
focused primarily on factors that regulate the differenti-
ation of myofibroblasts from stromal fibroblasts. Trans-
forming growth factor (TGF)-β is a potent inducer of
the myofibroblast phenotype and TGFβ-induced differ-
entiation of fibroblasts to myofibroblasts was found to
depend on the ED-A domain of fibronectin [41]. Hall-
marks of differentiated myofibroblasts include de novo
expression of alpha smooth muscle actin (αSMA) and
the incorporation of αSMA into stress fibers whichconfers high contractile activity to myofibroblasts. In this
process, mechanical tension is crucial for the develop-
ment of contractile features and for the acquisition of a
myofibroblast phenotype [42-46]. Culture of fibroblasts
on two-dimensional compliant substrata or within three-
dimensional collagen gels has revealed that increased mi-
croenvironmental stiffness and tension results in increased
differentiation of fibroblasts to myofibroblasts [43,47]. In
vitro and in vivo experiments have also shown that chan-
ges in tensional loads to either collagen gels with embed-
ded fibroblasts or granulation tissue at wound sites results
in altered contractility of myofibroblasts [48,49]. Likewise,
myofibroblasts can actively remodel both the chem-
ical and physical properties of their microenvironment
through the secretion of ECM and exertion of contractile
forces [50]. Thus, mechanical signals are essential for the
development of myofibroblasts from fibroblasts and for
proper physiological function.
Epithelial cells mediate fibrogenesis
Epithelial-mesenchymal transition (EMT) is a form of
epithelial plasticity that is important in normal embry-
onic development and is co-opted in the progression of
pathological conditions including fibrosis and cancer
[51-54]. In EMT, epithelial cells, which form monolayers
that line many body structures and compartments, loo-
sen attachments to neighboring cells, acquire an elonga-
ted morphology, and display increased motility (Figure 1).
In addition to these phenotypic shifts, cells exhibit alter-
ations in gene expression including upregulation of a var-
iety of transcription factors including Snail, Slug, and
Twist, decreased expression of epithelial markers such as
E-cadherin and cytokeratins, and de novo expression of
mesenchymal markers such as N-cadherin and vimentin
[51,55]. Following early EMT marker changes, further pro-
gression through EMT can stimulate a myogenic program
characterized by the expression of αSMA and a myofibro-
blast phenotype [56]. EMT is believed to contribute to
fibrogenesis by serving as a source of myofibroblasts and
by promoting paracrine signaling between epithelial
cells and stromal cells. Several recent reviews highlight
the role of EMT in epithelial-mesenchymal interactions in
the context of fibrotic diseases [57-59].
Many studies have identified cells demonstrating fea-
tures of EMT in fibrotic disease models and in human
biopsy samples. In a model of liver fibrosis, hepatocytes
upregulate the expression of the EMT-associated tran-
scription factor Snail and hepatocyte-specific ablation of
Snail protects mice from fibrotic progression [60]. In
this study, it was found that hepatocyte expression of
Snail has a multifaceted effect on the progression of liver
fibrosis through regulation of growth factor expression
and ECM synthesis, which impacts hepatocytes them-
selves and other cell types. Furthermore, hyperplastic type
Figure 1 Schematic representation of epithelial-mesenchymal transition. EMT is a process in which epithelial cells disaggregate and exhibit
dramatic shape changes. The transitioning epithelial cells lose polarity and intercellular contacts and gain mesenchymal properties such as
increased migratory capacity, contractility, and production of extracellular matrix proteins. Common protein markers of epithelial and mesenchymal
phenotypes are listed.
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idiopathic pulmonary fibrosis co-express epithelial and
mesenchymal markers including αSMA [61-63]. In ad-
dition, human renal biopsy samples from patients with a
variety of fibrotic kidney diseases display cells within the
tubular structures that exhibit both epithelial and mesen-
chymal features [64,65]. Together, these findings lend
strong support for an important role for the epithelium in
fibrogenesis either as a precursor of myofibroblasts or as a
mediator influencing the development of myofibroblasts
from other cell types.
Given the importance of myofibroblasts in health and
disease, much effort has been directed toward identifica-
tion of myofibroblast progenitor cell types through li-
neage tracing studies in in vivo disease models. Studies
have revealed a variety of candidates including resident
fibroblasts, mesenchymal stem cells, and endothelial cells,
with a number of reports finding that a portion of myofi-
broblasts within fibrotic lesions arise from epithelium
through EMT [27,61,66-71]. Fate tracking of alveolar epi-
thelial cells in genetically modified mice has demonstrated
that mesenchymal cells arising during the progression of
pulmonary fibrosis can originate from epithelial cells
[61,69,70]. Moreover, lineage tracing in animal models has
also identified epithelial cells as one of the cell types from
which myofibroblasts can originate in kidney, liver, and in-
testinal fibrosis with the proportion of myofibroblasts aris-
ing from epithelial cells being tissue specific [66,71,72].
However, a series of recent fate mapping studies using dif-
ferent epithelial and mesenchymal tags showed no evi-
dence of epithelial precursors to myofibroblasts in the
kidney and liver suggesting an alternate precursor cell type
or that the role of the epithelium in fibrogenesis may be
organ or disease specific [64,73-77]. Thus, whether epithe-
lial cells are indeed a source of myofibroblasts in vivo
is currently debated and yet to be resolved definitively.Several recent reviews provide a summary of the different
viewpoints with regard to this debate [58,64,73].
Biochemical induction of EMT by TGFβ
EMT is triggered by a variety of soluble factors including
epidermal growth factor (EGF), hepatocyte growth fac-
tor (HGF), fibroblast growth factor (FGF), and TGFβ
[55,78-85]. Other stimuli, such as hypoxia [86,87] and
adhesion to ECM components can also induce EMT
[69,88,89]. TGFβ, a ubiquitously expressed cytokine, is
a potent inducer of EMT and is regarded as a key me-
diator of wound healing [90,91], fibrosis [92,93], and
cancer [94,95]. Epithelial cells derived from a variety
of tissues including lung [69,96,97], kidney [98-101],
and breast [85,102-104] display myofibroblast features
following exposure to TGFβ. TGFβ is perhaps the best
characterized promoter of EMT and therefore we will
focus this review specifically on TGFβ-mediated EMT.
In the canonical TGFβ signaling pathway, active TGFβ
ligands initiate signaling by binding to type I and type II
receptor serine/threonine kinases. Following receptor ac-
tivation, Smad2 and Smad3 associate with the TGFβ re-
ceptor complex and are phosphorylated by the type I
TGFβ receptor. Phosphorylated Smad2 and Smad3 then
form a complex with Smad4 and translocate to the nu-
cleus. Once in the nucleus, the Smads can regulate the
transcription of target genes in conjunction with other
nuclear co-factors [105-107]. Activation of several Smad-
independent pathways including phosphoinositide 3-
kinase (PI3K)-Akt [108], focal adhesion kinase (FAK)
[109], p38 mitogen-activated protein kinase (p38MAPK)
[110], and extracellular signal-regulated kinase (Erk) [111]
have been identified as crucial for EMT induction by
TGFβ and recent studies implicate hyaluronan synthase 2
(HAS2) [112], Krüppel-like factor (KLF)-8 [113], and
microRNA miR-203 [114] as critical regulators of EMT.
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hibit dramatic cytoskeletal reorganization that is mediated
by signaling through the Rho GTPase pathway which
stimulates stress fiber formation, the acquisition of a mes-
enchymal morphology, and increased cytoskeletal con-
tractility. Evidence implicates the RhoA pathway as a
necessity for induction of EMT by TGFβ [108,115]. These
changes in cell morphology and cytoskeletal architecture
suggest an important role for physical cues in regulating
EMT.
Mechanical activation of TGFβ
TGFβ is synthesized by cells and stored in a latent form
crosslinked to the ECM in the cellular microenviron-
ment. TGFβ can be activated via a number of mecha-
nisms, one of which is through integrin binding. Integrin
αvβ6, which is expressed at high levels predominantly on
injured epithelial cells or cancer cells [116], binds to and
locally activates TGFβ in vivo and in vitro [117]. Treat-
ment of lung epithelial cells with cytochalasin D, an
inhibitor of actin polymerization, blocks activation of
TGFβ by αvβ6 demonstrating an important role for the
actin cytoskeleton in inducing TGFβ bioactivity [117]. A
recent study suggests that cellular contractility is re-
quired for TGFβ activation by αvβ6 as treatment of lung
epithelial cells with Y27632 or blebbistatin, which inhibit
Rho associated kinase (ROCK) and non-muscle myosin
II respectively, abrogates TGFβ activation [118]. Myofi-
broblasts can also activate TGFβ through a combination
of αvβ5 and αvβ3 integrin engagement and contractile
forces in vitro [119]. Thus, cytoskeletal tension and cel-
lular force generation are key mediators of the activation
of TGFβ signaling.
EMT alters the mechanical properties of cells
Cellular mechanics are influenced in part by the combi-
nation of cell morphology and cytoskeletal organization
with the formation of stress fibers enabling increased
cellular contractility [120]. Atomic force microscopy
(AFM) is a useful tool to determine mechanical prop-
erties through gently applying a force to induce cell
deformation from which the modulus of the cell can
be determined. By employing AFM on kidney [121],
alveolar [122], and mammary [123] epithelial cells, re-
searchers have identified a significant increase in the
stiffness of cells following TGFβ treatment. Tension
within the membrane, as determined by tether pulling
experiments, was also found to increase after EMT in-
duction [123]. In addition, the topography of cells changes
following treatment with TGFβ with a rougher surface
profile [122] and nodular protrusions at intercellular junc-
tions accompanying the transition to a mesenchymal
phenotype [121]. These mechanical changes, in addition
to cytoskeletal rearrangements, demonstrate a correlationbetween cytoskeletal architecture and increased cell stiff-
ness as epithelial cells progress through EMT. Further-
more, EMT has been observed at the edges of epithelial
wounds [101,124] and AFM studies have found that cell
stiffness peaks approximately 10-20 μm from the wound
edge with lower localized mechanical stiffness at the
wound edge and far from the wound edge within the in-
tact epithelial monolayer [125]. This peak in mechanical
stiffness was nullified with the expression of a dominant
negative form of RhoA. These data suggest that wound
sites may serve as focal points for mechanical signaling
events and that changes in cellular stiffness may provide
signals for cellular processes including cell spreading and
migration which are required for the early stages of epi-
thelial wound healing.
Increased cell spreading and elongation promote EMT
The shape of a cell is regulated by microenvironmental cues
and has been shown to play a pivotal role in tissue morpho-
genesis [126,127], proliferation [128,129], apoptosis [128],
and differentiation [130-133]. Cell shape is a consequence
of intrinsic cellular mechanical properties and of forces
exerted on the cell due to its adhesion to environmental
components including ECM proteins and neighboring cells
[134,135]. During EMT, cells experience drastic shape
changes as they transition from a cuboidal, cobblestone
morphology characteristic of epithelial cells to an elongated,
spindle-like shape typical of mesenchymal cells.
Through the use of micropatterned cell culture sub-
strata, which enable precise control over cell spreading,
studies have shown that cell shape regulates the expres-
sion levels of the epithelial marker cytokeratin and the
mesenchymal marker vimentin in matrix metalloprotein-
ase (MMP)-3-induced EMT but not in TGFβ-induced
EMT [103]. More recently, we have demonstrated that
cell spreading and elongation are critical factors that re-
gulate TGFβ-induced expression of the myofibroblast
marker αSMA during EMT [104]. Culturing epithelial
cells on microcontact printed islands of fibronectin of
varying sizes and shapes enabled control of cell mor-
phology. Adhesion to large square islands (2500 μm2)
which permitted cells to spread promoted an increase in
the percentage of cells expressing αSMA after 48 hours
of TGFβ treatment in comparison to cells blocked from
spreading (400 μm2) and to control cells not treated with
TGFβ (Figure 2A). We found that cell shape regulates
αSMA expression in part by controlling the subcellular
localization of myocardin related transcription factor
(MRTF)-A (Figure 2B). MRTFA is a co-factor of serum
response factor (SRF) and together these proteins re-
gulate the transcription of a variety of genes associated
with actin dynamics and cell contractile function in-
cluding αSMA [136,137]. Indeed, MRTFA plays a key
role in TGFβ-induced EMT [138] and contributes to
Figure 2 Cell shape regulates epithelial-myofibroblast transition. (A) Immunofluorescence staining and quantification of TGFβ-induced
αSMA expression for mouse mammary epithelial cells cultured on 400 μm2 and 2500 μm2 fibronectin islands. The percentage of cells expressing
αSMA following a 48 hour treatment with TGFβ or control vehicle was determined by immunofluorescence staining and microscopy. Cells with
fluorescence intensities above background levels were scored as expressing αSMA. (B) Immunofluorescence staining for MRTFA in TGFβ-treated
NMuMG cells shows increased nuclear localization of MRTFA when cells are permitted to spread (2500 μm2) in comparison to when cell spreading is
blocked (400 μm2). MRTFA localization was determined by comparing the mean nuclear and cytoplasmic fluorescence intensities within cells. Dashed
lines represent the perimeter of the cell. Scale bars, 20 μm. Reported values are the mean of three independent experiments ± standard error of the
mean. *p < 0.05. (C) Proposed model demonstrating how cell spreading affects MRTFA subcellular localization and myofibroblast development.
Adapted from O’Connor and Gomez, 2013 [104].
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activity of MRTFA is regulated in part by its association
with monomeric (G)-actin and polymerization of actin
monomers into filamentous (F)-actin disrupts the as-
sociation between MRTFA and G-actin thus enabling
nuclear accumulation of MRTFA [141]. Increased cell
spreading promotes an increase in F-actin levels which
then leads to MRTFA nuclear localization and tran-
scriptional activity (Figure 2C). These data suggest that
cell shape changes that accompany EMT are critical for
induction of the myofibroblast phenotype.
Matrix rigidity controls EMT
Microenvironmental physical properties, such as stiff-
ness and tension, are becoming increasingly acknowl-
edged as contributing to normal cellular processes and
to the development of diseases [142-145]. In wound
healing, fibrosis, and cancer, epithelial cells exist in aheterogeneous microenvironment in which the chemical
and mechanical properties are dynamic. For example,
during wound healing the mechanical properties at the
wound site evolve with time, from compliant (with a
Young's modulus of approximately 1 kPa) after initial
wounding to a stiffness of 25 kPa or greater for contract-
ing wound granulation tissue [146]. In fibrotic tissues, the
elastic modulus can reach values as high as 15-100 kPa
[147-150]. Interestingly, a recent study found that in-
creased microenvironmental rigidity may precede liver fi-
brosis suggesting that the mechanical properties of the
matrix may promote activation of pro-fibrotic pathways
[143,151]. In vivo and in vitro studies have also linked in-
creased tissue stiffness and collagen content to the tumor
phenotype and metastasis [144,145,152]. For example, du-
ring the progression of breast cancer, the stiffness of the
mammary gland can range from approximately 200 Pa for
normal tissue to 5000 Pa or greater for the average breast
O’Connor and Gomez Clinical and Translational Medicine 2014, 3:23 Page 6 of 13
http://www.clintransmed.com/content/3/1/23tumor [145,149,153]. High mammographic density, a
strong risk factor for breast cancer [154,155], is associated
with a significantly greater collagen content within the
mammary gland in comparison to breast tissue with less
mammographic density [4].
Recent studies have identified matrix rigidity as a cru-
cial regulator of TGFβ-induced EMT through several
pathways [99,118,147,156]. Mammary and kidney epi-
thelial cells exhibit a switch between TGFβ-induced
apoptosis and EMT when cultured on compliant or ri-
gid substrata, respectively [99]. In these studies, soft
substrata blocked and rigid substrata promoted EMT
regardless of whether the cells were cultured on fibro-
nectin, collagen I, or recombinant basement membrane.
The switch between apoptosis and EMT is controlled by
activation of the PI3K/Akt signaling pathway, with in-
creasing matrix rigidity promoting increased phospho-
rylation of Akt. Furthermore, cells cultured on rigid
matrices are able to generate contractile forces which
promote TGFβ activation from its latent complex by αv
integrins while compliant matrices block this process
[118,119]. Activation of TGFβ on rigid substrata is pro-
moted by Rho/ROCK signaling in lung epithelial cells
and this induces EMT (Figure 3) [118,147,156]. On
fibronectin-coated substrata, this response can be abro-
gated by culturing cells on rigid substrata coated with a
fibronectin mutant which contains a stabilized RGD and
PHSRN synergy site that supports α3 and α5 integrin en-
gagement [156]. These results highlight the complex
interplay between epithelial cells and both the chemical
and physical properties of their microenvironment dur-
ing induction of EMT. Moreover, these studies suggest
that activation of EMT may create a positive feedback
loop that enhances myofibroblast activation and ECMFigure 3 Matrix rigidity promotes epithelial-myofibroblast transition.
primary alveolar type II cells cultured on fibronectin-coated polyacrylamide
glass. The alveolar epithelial cells undergo EMT on rigid substrata. Panel (A
activation of TGFβ from the latent complex. Adapted from Wells, 2013 [151
thus enabling release of TGFβ from its latent complex thereby increasing tsynthesis thereby further increasing the rigidity of the
matrix and disease progression.Tissue geometry patterns EMT
During tissue development and wound healing, cellular
behaviors are spatially patterned thus conferring cells at
specific locations unique attributes and functions. In-
deed, patterning within developing embryos is ensured
in part by the temporal and spatial regulation of EMT
[52]. Moreover, myofibroblasts have been observed at
the edges of epithelial wounds [101,124] and patholo-
gical EMT and myofibroblasts are found along the inva-
sion front of metastatic tumors [95,157,158].
Spatial variations in the mechanical properties of tis-
sues are controlled by tissue composition and architec-
ture as well as by the interaction of individual cells with
the surrounding matrix and neighboring cells. Within
epithelial tissues, neighboring cells exhibit cell-cell adhe-
sions that are mediated by tight junctions and adherens
junctions. These cell-cell junctions are functionally and
dynamically connected to the actin cytoskeleton thus en-
abling transmission of forces between neighboring cells.
In culture, intercellular transmission of mechanical stress
through cell-cell adhesions can establish mechanical gra-
dients with regions of maximal stress defined by the
geometry of the tissue [102,159]. Spatial patterns in EMT
can arise in two-dimensional epithelial sheets with down-
regulation of cytokeratins and upregulation of mesen-
chymal markers vimentin and αSMA occurring in regions
of the tissue that experience the highest mechanical
stresses [102]. The observed spatial patterning of TGFβ-
induced EMT correlates with the subcellular localiza-
tion of MRTFA, with EMT occurring in regions of the(A) Immunofluorescence staining for actin, E-cadherin, and αSMA for
gels of varying rigidity or on fibronectin (Fn) or laminin (Ln) coated
) is from Brown et al, 2013 [147]. (B) Schematic depicting the
]. Epithelial cells cultured on stiff matrices exhibit increased contractility
he amount of active TGFβ accessible to bind to cell surface receptors.
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localization.
Cyclic stretch promotes EMT
Some cells within the body experience cyclic stretch dur-
ing normal function, such as alveolar epithelia during
respiration. Under conditions associated with fibrosis,
epithelial cells may experience pathologically high levels
of stretch arising from tissue distortion associated with
injury or scar tissue formation. The effects of patho-
logical levels of stretch on the induction of EMT have
recently been highlighted in several studies. In a model
system examining the pathological effects of renal tubu-
lar distension, kidney epithelial cells exposed to cyclic
mechanical stretch exhibited increased EMT [160]. This
effect was mediated by upregulation of TGFβ by more
than two-fold in stretched cells in comparison to non-
stretched cells. Cyclic mechanical stretch also promotes
EMT in type II alveolar epithelial cells, not through up-
regulation of TGFβ, but rather by inducing actin po-
lymerization and upregulation of low molecular weight
hyaluronan which facilitates signaling through Wnt/
β-catenin and MyD88 pathways [161]. Together, these
studies demonstrate yet another important way in which
mechanical cues can promote EMT and the fibrotic re-
sponse of tissues to injury.
Mechanosensitive signaling cascades in EMT
Myocardin related transcription factors
Acquisition of mesenchymal features during TGFβ-
induced EMT is regulated in part by the SRF/MRTFA
signaling pathway and we have highlighted several studies
demonstrating the interplay between this pathway and
mechanics in EMT. Thus far, a majority of studies exam-
ining this pathway in the context of EMT have focused on
how MRTFA regulates the expression of cytoskeletal-
associated genes such as αSMA. MRTFA also regulates
the expression of EMT-associated transcription factors in-
cluding Snail, Slug, and Twist [105] and therefore may
have an impact on the expression of the epithelial gene
E-cadherin. Further studies are necessary to define the
role of MRTFA in the regulation of epithelial markers dur-
ing EMT and to determine the impact of mechanical cues
on the loss of epithelial features during EMT.
Hippo pathway
The Hippo pathway is critical for cell growth and cell
fate decisions and dysregulation of signaling through this
pathway or of its downstream effectors is implicated in
fibrosis and cancer [162-165]. Downstream effectors in
this pathway, Yes-associated protein (YAP) and trans-
criptional co-activator with PDZ-binding motif (TAZ),
interact with the canonical TGFβ signaling cascade by
regulating the subcellular localization of phosphorylatedSmads [166,167]. Activation of these factors is controlled
in part by cell-cell contact [167] and recent studies have
demonstrated that YAP and TAZ mediate how cells re-
spond to cell geometry and ECM elasticity to control cell
growth and stem cell differentiation [168-171]. Indeed,
cell shape and matrix rigidity modulate the subcellular
localization of YAP and TAZ and cytoskeletal destabiliza-
tion and inhibition of cell contractility inactivate YAP and
TAZ [168]. TAZ is a critical regulator of local EMT at
wound sites [172] and overexpression of TAZ can induce
EMT [173]. Downregulation of TAZ blocks αSMA expres-
sion along wound edges and it has been suggested that
TAZ may control αSMA expression either through associ-
ation with MRTFA or through interaction with the αSMA
promoter as a co-activator to the TEA domain (TEAD)
transcription factors [172]. Given that YAP and TAZ are
mechanosensitive and cytoskeletal architecture is linked
to Hippo pathway signaling [174], it is plausible that me-
chanical signals control YAP and TAZ activity to regulate
aspects of EMT. Future studies addressing the interplay of
mechanical cues and YAP and TAZ signal transduction
during TGFβ-induced EMT will be informative and may
shed light on mechanisms mediating fibrosis and cancer.
Targeting TGFβ-induced EMT
The multipotent nature of TGFβ signaling in normal
and diseased tissues presents challenges for the develop-
ment of therapeutics targeting this pathway. Nevertheless,
much effort has been directed toward the development of
antagonists of TGFβ [175-177]. Small molecule inhibitors
are in various stages of development [177] and clinical tri-
als are testing the efficacy of TGFβ monoclonal antibodies
for treatment of diabetic nephropathy and idiopathic pul-
monary fibrosis [58]. Furthermore, neutralizing antibodies
against TGFβ have been found to reduce metastatic can-
cer progression in mice [178-182]. In addition, a promis-
ing approach which has demonstrated efficacy as an
anti-fibrotic in lung, kidney, and liver disease models
is targeting the integrin- and contractility-induced ac-
tivation of TGFβ from it latent complex through the use
of a monoclonal antibody to αvβ6 integrin [183-186]. This
method may also be an effective therapeutic approach for
blocking tumor progression, as anti-αvβ6 integrin mono-
clonal antibody prevents xenograft tumor growth in vivo
[187]. Inhibiting TGFβ activation may present lower risk
to the disruption of beneficial effects of TGFβ than tar-
geting TGFβ itself since αvβ6 is expressed primarily
within epithelial cells and is highly upregulated in dis-
eased tissues [184].
Targeting intracellular signaling cascades downstream
of TGFβ rather than TGFβ itself may also be a viable ap-
proach for blocking fibrogenesis and cancer progression.
Indeed, a recent study demonstrated that troglitazone,
a peroxisome proliferator activated receptor (PPAR)-γ
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[188-190], attenuates TGFβ-induced phosphorylation of
Akt and upregulation of Snail [97]. This is one of the
major pathways activated within epithelial cells by the
combination of TGFβ and matrix rigidity [99]. In addition,
small molecule inhibitors including CCG-1423 and its an-
alogs block SRF/MRTFA signaling [191,192]. Namely,
CCG-1423 blocks the interaction of MRTFA with impor-
tin alpha/beta 1 thus preventing the nuclear import of
MRTFA [193]. Furthermore, CCG-1423 has been shown
to successfully inhibit TGFβ-induced expression of αSMA
[102,104,194]. Interestingly, a recent study reported that
the small molecule isoxazole can induce a myofibroblast
phenotype by regulating the stability and activity of MRTFA
[195]. Isoxazole enhanced cutaneous wound closure in
mice suggesting that therapeutics aimed at promoting
MRTFA signaling and the myofibroblast phenotype may
also be promising methods for improving wound healing.
Given the link between TGFβ-induced EMT, fibrosis,
and cancer, therapeutics directly targeting EMT may
prove to be fruitful approaches for treating these dis-
eases. Bone morphogenetic protein (BMP)-7 exhibits
anti-fibrotic effects in animal models of renal fibrosis
and reverses EMT in renal tubular cells in vitro [100,196].
Furthermore, a recent study found that a variety of anti-
proliferative agents also inhibit EMT suggesting that
the most effective compounds for cancer treatment may
be those that target multiple aspects of cancer progression
[197].
Conclusions
The ability of epithelial cells to transition to a mesenchy-
mal phenotype is regulated by cytokines, ECM com-
ponents, cell-cell contacts, and mechanical cues and a
combination of these factors is likely required for EMT
induction. The studies highlighted within this review
have identified an important role for mechanics in TGFβ-
induced EMT and suggest that mechanical signaling
pathways, including those involved in mechanotrans-
duction, cell contractility, and regulation of matrix ri-
gidity, could serve as potential targets for new therapies
directed toward fibrosis and cancer. To achieve this
though, a better understanding of the mechanistic un-
derpinnings of how cell and tissue level physical pro-
perties contribute to EMT in pathological settings is
needed.
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